

Edus H Warren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6974615/publications.pdf>

Version: 2024-02-01

102
papers

7,832
citations

57631

44
h-index

51492

86
g-index

103
all docs

103
docs citations

103
times ranked

9494
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Comprehensive assessment of T-cell receptor $\hat{\gamma}$ -chain diversity in $\hat{\gamma}$ \pm $\hat{\gamma}$ T cells. Blood, 2009, 114, 4099-4107. | 0.6 | 1,016 |
| 2 | Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood, 2011, 117, 3214-3219. | 0.6 | 544 |
| 3 | Overlap and Effective Size of the Human CD8 ⁺ T Cell Receptor Repertoire. Science Translational Medicine, 2010, 2, 47ra64. | 5.8 | 374 |
| 4 | Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK ϵ -modified donor T cells after allogeneic hematopoietic cell transplantation. Blood, 2006, 107, 2294-2302. | 0.6 | 314 |
| 5 | Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood, 2002, 100, 1201-1207. | 0.6 | 278 |
| 6 | Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood, 2013, 122, 1341-1349. | 0.6 | 243 |
| 7 | Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood, 2010, 115, 3869-3878. | 0.6 | 230 |
| 8 | Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood, 2004, 103, 347-352. | 0.6 | 225 |
| 9 | Cytotoxic T-Lymphocyte ϵ -Defined Human Minor Histocompatibility Antigens With a Restricted Tissue Distribution. Blood, 1998, 91, 2197-2207. | 0.6 | 224 |
| 10 | Effects of contralateral sound on auditory-nerve responses. I. Contributions of cochlear efferents. Hearing Research, 1989, 37, 89-104. | 0.9 | 223 |
| 11 | Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood, 2009, 114, 702-708. | 0.6 | 218 |
| 12 | A Human Minor Histocompatibility Antigen Resulting from Differential Expression due to a Gene Deletion. Journal of Experimental Medicine, 2003, 197, 1279-1289. | 4.2 | 208 |
| 13 | The Immunogenicity of a New Human Minor Histocompatibility Antigen Results from Differential Antigen Processing. Journal of Experimental Medicine, 2001, 193, 195-206. | 4.2 | 191 |
| 14 | An Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order. Science, 2006, 313, 1444-1447. | 6.0 | 187 |
| 15 | The Human UTY Gene Encodes a Novel HLA-B8-Restricted H-Y Antigen. Journal of Immunology, 2000, 164, 2807-2814. | 0.4 | 161 |
| 16 | Dynamics of the Cytotoxic T Cell Response to a Model of Acute Viral Infection. Journal of Virology, 2015, 89, 4517-4526. | 1.5 | 146 |
| 17 | Effects of contralateral sound on auditory-nerve responses. II. Dependence on stimulus variables. Hearing Research, 1989, 37, 105-121. | 0.9 | 112 |
| 18 | Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight, 2016, 1, . | 2.3 | 111 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. <i>Blood</i> , 2017, 129, 791-798. | 0.6 | 109 |
| 20 | NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 565-586. | 2.0 | 107 |
| 21 | The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. <i>Blood</i> , 2006, 107, 3779-3786. | 0.6 | 99 |
| 22 | Non-Myeloablative Transplants for Malignant Disease. Hematology American Society of Hematology Education Program, 2001, 2001, 375-391. | 0.9 | 98 |
| 23 | Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. <i>Blood</i> , 2010, 115, 4923-4933. | 0.6 | 98 |
| 24 | Evaluation of published single nucleotide polymorphisms associated with acute GVHD. <i>Blood</i> , 2012, 119, 5311-5319. | 0.6 | 92 |
| 25 | Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. <i>American Journal of Hematology</i> , 2019, 94, E209-E213. | 2.0 | 92 |
| 26 | Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. <i>Nature Genetics</i> , 2009, 41, 1341-1344. | 9.4 | 91 |
| 27 | Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning. <i>Clinical Cancer Research</i> , 2004, 10, 7799-7811. | 3.2 | 89 |
| 28 | Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. <i>Blood</i> , 2012, 120, 2796-2806. | 0.6 | 84 |
| 29 | Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. <i>Blood</i> , 2017, 129, 2693-2701. | 0.6 | 80 |
| 30 | A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. <i>Clinical Cancer Research</i> , 2018, 24, 3519-3527. | 3.2 | 80 |
| 31 | Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. <i>Current Opinion in Hematology</i> , 1998, 5, 429-433. | 1.2 | 76 |
| 32 | Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 456-463. | 0.6 | 75 |
| 33 | Tracking the fate and origin of clinically relevant adoptively transferred CD8 ⁺ T cells in vivo. <i>Science Immunology</i> , 2017, 2, . | 5.6 | 68 |
| 34 | The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. <i>Blood Reviews</i> , 2003, 17, 153-162. | 2.8 | 66 |
| 35 | Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. <i>Blood</i> , 2012, 119, 5492-5501. | 0.6 | 66 |
| 36 | DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. <i>Blood</i> , 2008, 111, 4817-4826. | 0.6 | 62 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | <i>C19orf48</i> Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 5260-5269. | 3.2 | 59 |
| 38 | Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. <i>Blood</i> , 2015, 125, 3193-3201. | 0.6 | 59 |
| 39 | HLA-F and MHC-I Open Conformers Cooperate in a MHC-I Antigen Cross-Presentation Pathway. <i>Journal of Immunology</i> , 2013, 191, 1567-1577. | 0.4 | 58 |
| 40 | Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells. , 2014, 2, 36. | | 57 |
| 41 | A Novel HLA-A*3303-Restricted Minor Histocompatibility Antigen Encoded by an Unconventional Open Reading Frame of Human TMSB4Y Gene. <i>Journal of Immunology</i> , 2004, 173, 7046-7054. | 0.4 | 56 |
| 42 | Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. <i>Cancer Medicine</i> , 2016, 5, 2567-2578. | 1.3 | 56 |
| 43 | Graft versus Leukemia Reactivity after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S33-S38. | 2.0 | 55 |
| 44 | Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. <i>British Journal of Haematology</i> , 2003, 123, 671-675. | 1.2 | 49 |
| 45 | Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1380-1384. | 2.0 | 49 |
| 46 | Effects of Mismatching for Minor Histocompatibility Antigens on Clinical Outcomes in HLA-Matched, Unrelated Hematopoietic Stem Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 856-863. | 2.0 | 47 |
| 47 | Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2010, 17, 483-492. | 1.2 | 45 |
| 48 | Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer. <i>Journal of Immunotherapy</i> , 2012, 35, 131-141. | 1.2 | 45 |
| 49 | Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 4759-4768. | 3.2 | 41 |
| 50 | Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity. <i>Journal of Immunology</i> , 2019, 202, 476-483. | 0.4 | 41 |
| 51 | Adoptive Transfer of Allogeneic Antigen-Specific T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 9-12. | 2.0 | 39 |
| 52 | A Single Minor Histocompatibility Antigen Encoded by UGT2B17 and Presented by Human Leukocyte Antigen-A*2902 and -B*4403. <i>Transplantation</i> , 2007, 83, 1242-1248. | 0.5 | 35 |
| 53 | Phenotypic and Transcriptional Fidelity of Patient-Derived Colon Cancer Xenografts in Immune-Deficient Mice. <i>PLoS ONE</i> , 2013, 8, e79874. | 1.1 | 34 |
| 54 | T-Cell Therapy of Leukemia. <i>Cancer Control</i> , 2002, 9, 114-122. | 0.7 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology. <i>Blood</i> , 2013, 122, 19-22. | 0.6 | 33 |
| 56 | Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 2450-2456. | 0.6 | 32 |
| 57 | Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. <i>Lancet Haematology</i> , 2021, 8, e562-e571. | 2.2 | 28 |
| 58 | High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis. <i>Blood Advances</i> , 2017, 1, 535-544. | 2.5 | 27 |
| 59 | Applications of Next-Generation Sequencing to Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S151-S160. | 2.0 | 20 |
| 60 | Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL. <i>American Journal of Hematology</i> , 2019, 94, E117-E116. | 2.0 | 19 |
| 61 | Genetic risk factors for sclerotic graft-versus-host disease. <i>Blood</i> , 2016, 128, 1516-1524. | 0.6 | 18 |
| 62 | Abnormalities of the $\alpha\beta$ T-cell receptor repertoire in advanced myelodysplastic syndrome. <i>Experimental Hematology</i> , 2010, 38, 202-212. | 0.2 | 17 |
| 63 | A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1308-1315. | 2.0 | 17 |
| 64 | Activation and Expansion of CD8+ T Effector Cells in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1121-1132. | 2.0 | 17 |
| 65 | Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1979-1993. | 2.0 | 17 |
| 66 | T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 868-882. | 2.0 | 15 |
| 67 | Improving Hematopoietic Cell Transplant Outcomes in a New Era of Genomic Research. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 42-45. | 2.0 | 13 |
| 68 | A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 170-177. | 0.4 | 13 |
| 69 | Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 559-564. | 1.1 | 12 |
| 70 | RNA helicase, DDX3X, is actively recruited to sites of DNA damage in live cells. <i>DNA Repair</i> , 2021, 103, 103137. | 1.3 | 12 |
| 71 | Precision Medicine in Low- and Middle-Income Countries. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 387-402. | 9.6 | 11 |
| 72 | The Impact of B-cell Directed Therapy on SARS-CoV-2 Vaccine Efficacy in CLL. <i>British Journal of Haematology</i> , 2022, , . | 1.2 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. <i>Practical Radiation Oncology</i> , 2020, 10, 44-52. | 1.1 | 10 |
| 74 | Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1882-1896. | 1.4 | 10 |
| 75 | HLA and TCR Knockout by Zinc Finger Nucleases: Toward "off-the-Shelf" Allogeneic T-Cell Therapy for CD19+ Malignancies.. <i>Blood</i> , 2010, 116, 3766-3766. | 0.6 | 10 |
| 76 | Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 763-773. | 1.4 | 8 |
| 77 | CD8+ T-cell Clones Specific for the 5T4 Antigen Target Renal Cell Carcinoma Tumor-initiating Cells in a Murine Xenograft Model. <i>Journal of Immunotherapy</i> , 2012, 35, 523-533. | 1.2 | 8 |
| 78 | Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 77. | 2.8 | 8 |
| 79 | CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells. <i>Nature Communications</i> , 2022, 13, 78. | 5.8 | 8 |
| 80 | Identification of Novel MHC Class II-Restricted Male-Specific mHAg Encoded bySMCY(JARID1D)... <i>Blood</i> , 2009, 114, 1344-1344. | 0.6 | 7 |
| 81 | Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 390-395. | 0.2 | 6 |
| 82 | Capacity building for hematologic malignancies in Uganda: a comprehensive research, training, and care program through the Uganda Cancer Instituteâ€“Fred Hutchinson Cancer Research Center collaboration. <i>Blood Advances</i> , 2018, 2, 8-10. | 2.5 | 5 |
| 83 | Serial Analysis of the T-Cell Receptor Î²-Chain Repertoire in People Living With HIV Reveals Incomplete Recovery After Long-Term Antiretroviral Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 879190. | 2.2 | 5 |
| 84 | High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma. <i>JCO Precision Oncology</i> , 2021, 5, 602-612. | 1.5 | 4 |
| 85 | Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e87-e90. | 0.2 | 3 |
| 86 | Minor histocompatibility antigens in allogeneic hematopoietic cell transplantation. <i>Current Opinion in Organ Transplantation</i> , 2006, 11, 31-36. | 0.8 | 2 |
| 87 | Genetic risk for colitis-associated colorectal cancer. <i>Gut</i> , 2009, 58, 1177-1179. | 6.1 | 2 |
| 88 | Generation of CD8+ Cytotoxic T Cell Clones Recognizing BMI1-Derived Peptides. <i>Blood</i> , 2008, 112, 2909-2909. | 0.6 | 2 |
| 89 | Heterologous <sc>SARSâ€“CoV</sc>â€“2 vaccinations in patients with Bâ€“cell lymphoid malignancies. <i>American Journal of Hematology</i> , 2022, 97, . | 2.0 | 2 |
| 90 | Determination of Intronic Sequences Adjacent to an Exon Using Polymerase Chain Reaction and Genomic DNA Library Constructed by TA Cloning. <i>Analytical Biochemistry</i> , 2001, 289, 289-292. | 1.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Diversifying the MHC peptide portfolio. <i>Blood</i> , 2012, 120, 3165-3167. | 0.6 | 1 |
| 92 | The Human Graft-versus-Tumor Response“ and How to Exploit It. , 0, , 232-247. | | 1 |
| 93 | High-throughput sequencing reveals novel features of immunoglobulin gene rearrangements in Burkitt lymphoma. <i>Blood Advances</i> , 2017, 1, 1261-1262. | 2.5 | 1 |
| 94 | Blazing a trail in T-cell recognition. <i>Blood</i> , 2011, 117, 4681-4682. | 0.6 | 0 |
| 95 | Laboratory Correlates of Immune Reconstitution At 1-Year Following Related, Unrelated, and Umbilical Cord Blood Hematopoietic Stem Cell Transplantation: Correlation with Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S204-S205. | 2.0 | 0 |
| 96 | Evolution and Clinical Implications of the T Cell Repertoire Following Cord Blood Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S201-S202. | 2.0 | 0 |
| 97 | T-Cell Receptor Sequencing of Kaposi Sarcoma Tumors to Identify Candidate Tumor-Reactive T Cells. <i>Journal of Global Oncology</i> , 2017, 3, 45s-45s. | 0.5 | 0 |
| 98 | Adoptive Immunotherapy of Human Diseases with Antigen-Specific T-Cell Clones. , 2000, , 29-44. | | 0 |
| 99 | Abstract 4778: Epigenetic modulation of colorectal cancer cells for cancer-testis antigen-targeted immunotherapy. , 2010, , . | | 0 |
| 100 | Abstract B49: Autologous T cell responses against patient-derived colorectal cancer xenografts.. , 2013, , . | | 0 |
| 101 | Patterns of disease progression in advanced non-small cell lung cancer patients treated with PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20607-e20607. | 0.8 | 0 |
| 102 | Abstract 2552: Preclinical development of T-cell receptor therapy targeting the 5T4 tumor antigen on renal cell carcinoma. , 2018, , . | | 0 |